Pharma-Bio Serv FY2026 EPS Forecast Cut by Zacks Research

Pharma-Bio Serv Inc. (OTCMKTS:PBSV) – Research analysts at Zacks Research cut their FY2026 EPS estimates for shares of Pharma-Bio Serv in a research report issued to clients and investors on Tuesday, September 15th. Zacks Research analyst B. Sorensen now forecasts that the company will post earnings per share of $0.04 for the year, down from their prior forecast of $0.07. The consensus estimate for Pharma-Bio Serv’s current full-year earnings is $0.07 per share.

Pharma-Bio Serv Stock Performance

Pharma-Bio Serv stock opened at $0.40 on Wednesday. Pharma-Bio Serv has a fifty-two week low of $0.40 and a fifty-two week high of $1.36. The business’s 50-day simple moving average is $0.51 and its two-hundred day simple moving average is $0.52. The company has a market cap of $9.16 million, a PE ratio of 40.04 and a beta of 0.71.

Pharma-Bio Serv (OTCMKTS:PBSV) last issued its quarterly earnings results on Monday, June 15th. The company reported $0.01 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). The company had revenue of $2.70 billion for the quarter, compared to analyst estimates of $2.70 million. Pharma-Bio Serv had a net margin of 2.66% and a return on equity of 2.32%.

About Pharma-Bio Serv

Pharma-Bio Serv, Inc operates as a compliance and technology transfer services consulting firm in Puerto Rico, the United States, Europe, Brazil, and internationally. The company provides technical compliance consulting services comprising regulatory compliance, validation, technology transfer, engineering, project management, and process support for the pharmaceutical, chemical manufacturing, biotechnology, medical device, cosmetic, food industries, and allied products companies. Pharma-Bio Serv, Inc was founded in 1993 and is headquartered in Dorado, Puerto Rico.